@EU_Startups
üzerinden X
Breye Therapeutics, a Danish clinical-stage #biopharmaceutical company developing #oral #therapeutics for the early treatment of #retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. 🇩🇰 👁️ 💊

https://t.co/T9Qc1TAgKE
Sona ulaştın 🎉

Çerezler bu web sitesini normal bir şekilde kullanmana ve bu web sitesindeki deneyimini kişiselleştirmene olanak sağlar.

>>Daha fazla bilgi